Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...

Genetic differences that contribute to how long a person will live and their risk of Alzheimer's disease have been identified ...

2024 — Beta-blocker drugs -- commonly used to treat heart and blood pressure issues -- may slow the progression of Huntington's disease (HD), according to a new ... 'Alzheimer's in Dish' Model ...

(OTCQB: BIXT) (the "Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its ...

Summary: A new study has identified a biomarker, DTI-ALPS, which connects glymphatic system dysfunction to vascular dementia.

A chronic gut infection caused by a common virus may be linked to the progression of Alzheimer ’s disease, a new study has ...

Nearly 7 million Americans have been diagnosed with dementia, which slowly erodes memory, thinking skills and the ability to ...

A study from the Keck School of Medicine of USC has tested a biomarker linked to vascular dementia across four separate ...

Roche Holding, Novartis, and Eli Lilly & Company Dominate the Competitive Landscape Global Central Nervous System ...